MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.380
+0.020 (1.47%)
At close: Mar 9, 2026, 4:00 PM EDT
1.380
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
MediciNova Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 68 | 64 | 103 | 74 | 101 | 131 | |
| Market Cap Growth | -22.01% | -37.49% | 40.00% | -26.83% | -23.50% | -44.38% | |
| Enterprise Value | 37 | 32 | 61 | 23 | 49 | 57 | |
| Last Close Price | 1.38 | 1.31 | 2.10 | 1.50 | 2.05 | 2.68 | |
| PS Ratio | 165.81 | 157.16 | - | 73.57 | - | 32.55 | |
| PB Ratio | 1.63 | 1.55 | 1.96 | 1.18 | 1.43 | 1.57 | |
| P/TBV Ratio | 2.50 | 2.37 | 2.70 | 1.53 | 1.80 | 1.90 | |
| EV/Sales Ratio | 91.13 | 78.30 | - | 22.73 | - | 14.19 | |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net Debt / Equity Ratio | -0.74 | -0.74 | -0.76 | -0.81 | -0.82 | -0.84 | |
| Net Debt / EBITDA Ratio | 2.31 | 2.31 | 3.16 | 5.10 | 3.96 | 6.93 | |
| Net Debt / FCF Ratio | 3.12 | 3.12 | 3.75 | 6.76 | 4.47 | 7.50 | |
| Asset Turnover | 0.01 | 0.01 | - | 0.01 | - | 0.05 | |
| Quick Ratio | 8.11 | 8.11 | 13.64 | 15.55 | 18.35 | 25.22 | |
| Current Ratio | 8.16 | 8.16 | 13.88 | 15.61 | 18.51 | 25.42 | |
| Return on Equity (ROE) | -25.50% | -25.50% | -19.24% | -12.93% | -18.28% | -13.08% | |
| Return on Assets (ROA) | -16.36% | -16.36% | -12.97% | -8.81% | -11.32% | -7.84% | |
| Return on Capital Employed (ROCE) | -31.80% | -31.80% | -24.00% | -15.70% | -20.60% | -12.10% | |
| Earnings Yield | -17.66% | -18.64% | -10.73% | -11.65% | -13.99% | -7.71% | |
| FCF Yield | -14.45% | -15.24% | -10.33% | -10.13% | -12.85% | -7.16% | |
| Buyback Yield / Dilution | -0.03% | -0.03% | - | -0.00% | -0.92% | -9.42% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.